If you are wondering whether Pfizer's current share price properly reflects its long term potential, the recent share ...

Pfizer (PFE) recently reported a revenue decline tied to weaker COVID product sales and a US$4.4b impairment charge, while ...

Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one direction or another seems to ...

Pfizer (NYSE:PFE) received U.S. FDA Priority Review for a supplemental Biologics License Application covering PADCEV plus ...

Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company ...